Cowen initiates coverage on Immunomedics (NASDAQ: IMMU) with a Outperform rating and a price target of $15.00.
Analyst Dr. Phil Nadeau comments "Immunomedics' lead candidate IMMU-132 has produced compelling Ph. II data in the treatment of relapsed/refractory mTNBC and our physician consultants expect IMMU-132 to become part of the standard of care. We project a FY2019 launch, and that IMMU-132 will achieve $720MM in worldwide revenue in mTNBC by 2025."
FY 2017 EPS estimate is for a loss of $1.10 and FY 2018 EPS estimate is for a loss of $0.70.
For an analyst ratings summary and ratings history on Immunomedics click here. For more ratings news on Immunomedics click here.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.